Understanding immune responses to SARS CoV2 infection and vaccination

Alessandro Sette

THE TEAM


Prof. Alex Sette


Alba Grifoni, PhD


Alison Tarke


Ricardo Da Silva Antunes, PhD


Esther Yu Dawan, MD


John Sidney


Prof. Daniela Weiskopf


April Frazier PhD


Prof. Shane Crotty


Camila Coelho,PhD


Zeli Zhang, PhD


Prof. Jen Dan MD/PhD


Jose Mateus, PhD


Nils Methot


Eric Wang


Paul Rubiro

<u>Crotty Lab</u>
Carolyn Rydyznski Moderbacher
Sydney Ramirez
Prof. Jennifer Dan
Yu 'Alex' Kato
Simon Belanger
Katia Faliti
Christina Kim
Robert Abbott
Eleanor Crotty
Jinyong Choi
Sonya Haupt
Zeli Zhang
Nate Bloom
Ben Goodwin

<u>Sette Lab</u>
Alba Grifoni
Alison Tarke
Esther Yu
Ricardo Antunes
Nils Methot
Jenna Memollo
April Frazier
John Sidney
Paul Rubiro

<u>Weiskopf Lab</u>
Jose Mateus
James Chang

<u>Peters Lab</u>
Bjoern Peters

<u>LJI Bioinformatics Core</u>
Jason Greenbaum

<u>Clinical Studies Core</u>
Gina Levi
Shariza Bautista
Quinn Bui
Jasmine Cardenas

<u>UCSD</u>
Stephen Rawlings
Davey Smith

<u>LJI Flow Cytometry Core</u>
Denise Hinz
Cheryl Kim

<u>JCVI</u>
Richard Scheuermann

<u>Vanderbilt University</u>
Simon Mallal

NIH National Institute of Allergy and Infectious Diseases

Philanthropic Support

SARS-CoV-2 should be immunogenic

- Scarce data initially available
- Strong sequence homology and structural similarity with SARS-CoV1
- Similarity also at the epitope level
- Predicted CD4 and CD8 epitopes in SARS CoV2
- Enable experimental testing

Alba Grifoni, PhD



Grifoni et al., Cell Host & Microbe March 2020

Do people develop immunity to SARS CoV2?

Antibodies
(from B cells)

- Important in almost all currently licensed human vaccines



Helper T cells

- Critical for antibody responses
- Protect independent of antibodies in SARS mouse model



Killer T cells

- Important in many viral infections
- Critical to eliminate infected cells

T cell and antibody responses in ‘mild’ cases of COVID-19

Cell

Article

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Graphical Abstract



Authors

Alba Grifoni, Daniela Weiskopf, Sydney I. Ramirez, ..., Davey M. Smith, Shane Crotty, Alessandro Sette

Correspondence

shane@lji.org (S.C.), alex@lji.org (A.S.)

In Brief

An analysis of immune cell responses to SARS-CoV-2 from recovered patients identifies the regions of the virus that is targeted and also reveals cross-reactivity with other common circulating coronaviruses



LJI reagents to measure T cells : shared with 185 labs, 32 different countries, 6 continents and resulted in over 50 collaborative studies

Grifoni et al., Cell May 2020

SARS-CoV-2 immune memory following natural infection

- The largest ever study of its kind, for any infection
- Substantial immune memory in most individuals at 8+ months post-COVID
- Immune memory is complex and heterogenous
- T cells, memory B cells, and antibodies have different kinetics
- 5-10% of individuals have low level immune memory at 6+ months




The New York Times

Immunity to the Coronavirus May Last Years, New Data Hint

Blood samples from recovered patients suggest a powerful, long-lasting immune response, researchers reported.

Asst. Prof. Jen Dan MD/PhD

Dan et al. Science. Jan 2021

Evidence pointing to substantial contributions of T cells to SARS CoV2 immunity

- Early T cell responses correlate with better outcomes and lower viral loads
- CD8 T cells provide control in monkeys
- People lacking antibodies resolve SARS CoV2 infections
- Onset of protection from Moderna or Pfizer vaccines in absence of detectable neutralizing antibodies



Moderbacher et al. Cell Sept 2020



Tan et al, Cell Rep, 2021



Kalimuddin Cell Med, 2021

Vaccine protection against SARS-CoV-2

Protection against
Detectable Infection



Major

Protection against
Hospitalizations & Deaths



Minor

Comparison of immune memory to four COVID-19 vaccines



mRNA-1273-100 µg



BNT162b2-30µg



NVX-CoV2373



J&J

Characteristic	mRNA-1273 Moderna	BNT162b2 Pfizer	Ad26.COV2.S Janssen	NVX-CoV2373 Novavax
Donors, n	30	30	30	12
Gender, n (%)				
Male	12 (40%)	11 (37%)	11 (37%)	6 (60%)
Female	18 (60%)	19 (63%)	19 (63%)	4 (40%)
Age, years (mean ± SD)	43.6 ± 13.9	43.2 ± 17.4	45.6 ± 14.9	38.3 ± 18.0
Race or ethnicity, n				
Asian	3	9	2	0
White	24	16	24	11
Hispanic or latino	9	5	5	1
Days post-vaccination (mean ± SD)				
T2	15 ± 4	15 ± 2	15 ± 3	-
T3	45 ± 6	37 ± 3	47 ± 8	-
T4	105 ± 6	106 ± 4	108 ± 7	120 ± 19
T5	185 ± 9	184 ± 8	185 ± 3	185 ± 11



Crotty, Sette, Weiskopf and colleagues
biorxiv

Comparison of immune memory to four COVID-19 vaccines





Zeli Zhang, PhD

Jen Dan, MD/PhD

PSV, Pseudovirus

Figures modified from Zhang et al. *bioRxiv* 2022.03.18.484953; doi: https://doi.org/10.1101/2022.03.18.484953

Comparison of immune memory to four COVID-19 vaccines





Carolyn Rydyznski Moderbacher, PhD

100% of individuals made memory CD4+ T cells, with Tfh highly represented after mRNA or Novavax vaccination. CD4-CTL were also unexpectedly common

CTL, Cytotoxic T-Lymphocyte; Tfh, follicular helper T cells

Figures modified from Zhang et al. *bioRxiv* 2022.03.18.484953; doi: https://doi.org/10.1101/2022.03.18.484953

Comparison of immune memory to four COVID-19 vaccines



Jose Mateus, PhD

mRNA vaccines and J&J induced comparable CD8+ T cell frequencies, though memory CD8+ T cells were only detectable in 60-67% of subjects at 6 months

Figures modified from Zhang et al. *bioRxiv* 2022.03.18.484953; doi: https://doi.org/10.1101/2022.03.18.484953

Comparison of immune memory to four COVID-19 vaccines





Camila Coelho, PhD

Spike- and RBD-specific memory B cell responses were detected in all individuals to each of the four vaccines, and their frequency increased over time

RBD, Receptor-Binding Domain

Figures modified from Zhang et al. *bioRxiv* 2022.03.18.484953; doi: https://doi.org/10.1101/2022.03.18.484953

Comparison of immune memory to four COVID-19 vaccines









What about variants?



Breadth of SARS CoV2-specific CD4 and CD8 T cell responses

- Identified 280 different CD4 and 523 different CD8 epitopes
- Each individual recognizes multiple epitopes and antigens; conservative estimate of 30-40 epitopes recognized per donor

Tarke et al., Cell Med Rep Jan 2021

- Metanalysis of SARS CoV2 human T cell epitopes; 2049 different human SARS-CoV-2 T cell epitopes defined so far

Grifoni et al., Cell Host & Microbe May 2021



Elemans M, Seich al Basatena N-K, Asquith B (2012) PLoS Comput Biol 8(2): PMID: 22383867

T cell reactivity to SARS-CoV-2 variants in vaccinated individuals





Alba Grifoni, PhD

Alison Tarke

Tarke A et al, Grifoni and Sette. Cell. Jan 2022 PMID: 35139340

T cell recognition of Omicron is preserved



Tarke A et al, Grifoni and Sette. Cell. Jan 2022 PMID: 35139340



Tarke A et al, Grifoni and Sette. Cell. Jan 2022 PMID:35139340



- ❑ Keeton et al., Nature 2022; South Africa
- ❑ GeurtsvanKessel et al.,2022 Sci Imm; Netherlands
- ❑ Gao et al., Nat Med 2022; Sweden
- ❑ Madelon et al., JAMA Neur 2022; Switzerland

Vaccine protection against SARS-CoV-2

Protection against
Detectable Infection



Major

Protection against
Hospitalizations & Deaths



Minor

Waning protection against Detectable Infection



Minimal waning protection against Hospitalizations & Deaths



Kaiser study
Tartof et al. Lancet 2021. PMID 34619098


Nasal
Oral/Salivary
Lung


Unvaccinated
Asymptomatic
Pauci-symptomatic
Cold-like
Flu-like
Hospitalized
ICU
Fatal
Vaccinated
Infection
Recent/ wild type
No Infection
Infection
6 months Ago/ variants
No Infection
Asymptomatic
Pauci-symptomatic
Cold-like
Flu-like
Hospitalized
Infection
Boosted
No Infection

Thoughts on booster vaccination (4th dose) authorized in USA for over 50

Mortality Reduction at Calit Health for Initial Booster and Second Booster



Eric Topol . Ground Truths March 29th

- Israeli studies show positive effects of a 4th immunization in the older age (Pzifer vaccine).
- However:
  - 3 immunizations already protect well from hospitalization and deaths, and short follow up are limitations
  - Antibodies levels restored to peak levels observed after the 3d shot.
  - No measure of T cell and B cell memory.
- Antibody titers contract more rapidly than cellular immunity, which tends to be more stable
- Still need to address long term effects on disease; we might be approaching a stage of limited returns on further immunizations.

Thoughts on booster vaccination (4th dose) authorized in USA for over 50



Eric Topol . Ground Truths March 29th

- Still there is value in the approval of the 4th immunization
  - new variants can dramatically alter the situation
  - protection offered by the third immunization might wane over time. particularly antibodies in older people.
- The authorization offers an important additional tool to manage the pandemic.
- In the current situation there is a continued need to monitor infections, hospitalizations and variants.

Where are we going? IgG CCC titers are sustained over the years



Ricardo Da Silva Antunes, PhD

Esther Yu Dawan, MD

Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period. bioRxiv. March 2022. PMID: 35262082

CD4+ T cell responses are also sustained over time



Pandemic preparedness. Beyond SARS CoV2



NIAID's approach to pandemic preparedness. *NIAID*

Reactivity is also detected in non-exposed individuals





- Pre-existing immunity could
  - influence the disease severity of subsequent SARS-CoV-2 infection
  - influence the outcome of SARS-CoV-2 vaccination

Alba Grifoni, PhD

Grifoni et al., Cell May 2020

Widespread evidence of cross-reactive T cell responses within coronaviruses





Jose Mateus, PhD

Mateus et al., Science, August 2020

Preexisting immune memory effect on low dose Moderna mRNA-1273 COVID-19 vaccine responses

Asst. Prof.
Daniela Weiskopf





	Day 1		Day 15		Day 43		Day 209	
Samples	17	18	17	18	15	17	15	17
Median	0.075	0.020	0.26	0.080	0.32	0.16	0.23	0.12
Responder (%)	100	0	100	94	100	100	100	94



	Day 1		Day 15		Day 43		Day 209	
Samples	17	18	17	18	15	18	15	18
GMT	3.4	3.1	107	44	1868	1312	182	147
Responder (%)	6	0	100	89	100	100	100	100

Mateus et al; Science, Sept 2021

Further evidence of cross-reactive T cells roles in prevention of symptomatic COVID-19

RESEARCH ARTICLE | CORONAVIRUS

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

LUCIE LOYAL, JULIAN BRAUN, LARISSA HENZE, BEATE KRUSE, MANUELA DINGELDEY, ULF REIMER, FLORIAN KERN, TATJANA SCHWARZ, MAIKE MANGOLD, [...] CLAUDIA GIESECKE-THIEL +28 authors Authors Info & Affiliations

SCIENCE • 8 Oct 2021 • Vol 374, Issue 6564 • DOI: 10.1126/science.abh1823

The Journal of Infectious Diseases

MAJOR ARTICLE

IDSA Infectious Diseases Society of America | hivma hiv medicine association | OXFORD

Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers

Ricardo da Silva Antunes,[1,a] Suresh Pallikkuth,[2,a] Erin Williams,[3,a] Esther Dawen Yu,[1] Jose Mateus,[1] Lorenzo Quiambao,[1] Eric Wang,[1] Stephen A. Rawlings,[4] Daniel Stadlbauer,[5] Kaijun Jiang,[5] Fatima Amanat,[5,6] David Arnold,[3] David Andrews,[7] Irma Fuego,[3] Jennifer M. Dan,[1,8] Alba Grifoni,[1] Daniela Weiskopf,[1] Florian Krammer,[5,9] Shane Crotty,[1,8] Michael E. Hoffer,[3,9,b] Savita G. Pahwa,[2,b] and Alessandro Sette[1,8,b]

ARTICLE

Check for updates

https://doi.org/10.1038/s41467-021-27674-x OPEN

Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts

Rhia Kundu[1,2✉], Janakan Sam Narean[1,2], Lulu Wang[1,2], Joseph Fenn[1,2], Timesh Pillay[1,2], Nieves Derqui Fernandez[1,2], Emily Conibear[1,2], Aleksandra Koycheva[1,2], Megan Davies[1,2], Mica Tolosa-Wright[1,2], Seran Hakki[1,2], Robert Varro[1,2], Eimear McDermott[1,2], Sarah Hammett[1,2], Jessica Cutajar[1,2], Ryan S. Thwaites[2], Eleanor Parker[3], Carolina Rosadas[3], Myra McClure[3], Richard Tedder[3], Graham P. Taylor[3], Jake Dunning[4,5] & Ajit Lalvani[1,2]

Comment on this paper

Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection

Leo Swadling, Mariana O. Diniz, Nathalie M. Schmidt, Oliver E. Amin, Aneesh Chandran, Emily Shaw, Corinna Pade, Joseph M. Gibbons, Nina Le Bert, Anthony T. Tan, Anna Jeffery-Smith, Cedric Tan, Christine Y. L. Tham, Stephanie Kucyowicz, Gloryanne Aidoo-Micah, Joshua Rosenheim, Jessica Davies, Melanie P. Jensen, George Joy, Laura E McCoy, Ana M Valdes, Lucy van Dorp, Daniel M. Altmann, Rosemary J. Boyton, Charlotte Manisty, Thomas A. Treibel, James C. Moon, COVIDsortium investigators, Francois Balloux, Áine McKnight, Mahdad Noursadeghi, Antonio Bertoletti, Mala K. Maini

JCI The Journal of Clinical Investigation

Recent endemic coronavirus infection is associated with less-severe COVID-19

Manish Sagar, ... , Laura F. White, Joseph P. Mizgerd

J Clin Invest. 2021;131(1):e143380. https://doi.org/10.1172/JCI143380.

Concise Communication COVID-19

Graphical abstract





Potential usefulness of cross-reactive HCoV-specific human T cells



- Cross-reactive T cell responses can modulate disease severity
- Several other coronaviruses are also of concern
- Is a ”pan-corona” or “pan-sarbeco” vaccine feasible?
- Experimentally determine epitopes/ regions that are widely crossreactive
- A T cell vaccine or vaccine component might be effective in broadly preventing severe disease and death

J. Craig Venter™ INSTITUTE

Alba Grifoni, PhD

Alison Tarke

Thoughts on broadly crossreactive T cells

- T cell inducing vaccine components as a broad concept to enhance preparedness against future possible pandemics
- Strategy could be considered for virus families of pandemic preparedness concern (Arenav, Flavi, Bunya, Paramixo, Togav, Picorna and Filioviridae)
- Not an alternative to antibody strategies, but rather synergistic
- The human influenza T cell repertoire is broad and multispecific
- Human epitopes immunogenic conserved in Old and New world Arenaviruses
- Cross-reactivity of epitopes from multiple DENV serotypes and ZIKV



NIAID's approach to pandemic preparedness. *NIAID*

Overall Conclusions

- SARS CoV2 infection induces a multispecific and multifunctional adaptive responses which is durable over the 6-8 month period
- Neutralizing antibodies likely key to protect from infection, but substantial contributions of T cells likely at the level of protection from severe disease
- Side-by-side longitudinal comparison of different vaccine platforms reveals durable B and T cell responses, and allow correlation with vaccine efficacy
- T cell reactivity is largely preserved at the level of SARS CoV2 variants, including Omicron and Delta
- CCC cross-reactivity albeit rare, is detected and has biological relevance, with potential pandemic preparedness implications
- Responses to CCC are sustained in the adult population, offering a potential glimpse in endemicity



Adapted from Kaiser Study. (Tartof et al. Lancet 2021. PMID 34619098)